Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

Table 4

Risk of disease recurrence according to Cox regression test.

Variable	Univariate			Multivariate
	HR	CI 95%		HR	CI 95%
Male gender	1.014	0.3–3.1	0.98
No syndrome	3.064	0.4–23.6	0.282
GI-NET	1.874	0.6–5.8	0.276
Grading G2	6.578	2.0–21.8	0.002			ns
Stage IIIB-IV	105.304	1.0–10,718-1	0.048	105.154	2.1–3099.1	<0.000001
Low SSTR2A QS	2.886	0.8–10.6	0.11
Low IGF-1R QS	9.893	1.3–76.2	0.028			ns
High p-mTOR QS	3.700	1.2–11.1	0.02			ns

HR: hazard ratio; CI: confidence interval; ns: not statistically significant; GI-NET: gastrointestinal primary NET (versus pancreatic NET); SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score.